Zacks Research Analysts Boost Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Investment analysts at Zacks Research upped their Q4 2025 EPS estimates for BioMarin Pharmaceutical in a research note issued to investors on Monday, February 17th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $0.67 for the quarter, up from their previous estimate of $0.66. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.50 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q1 2026 earnings at $0.78 EPS.

Several other research analysts have also commented on the stock. StockNews.com raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 11th. Robert W. Baird decreased their price target on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Citigroup decreased their price target on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, December 12th. Finally, Evercore ISI decreased their price target on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Trading Up 0.0 %

NASDAQ BMRN opened at $64.86 on Wednesday. The firm has a 50 day simple moving average of $64.82 and a 200-day simple moving average of $71.24. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. BioMarin Pharmaceutical has a one year low of $60.63 and a one year high of $94.85. The firm has a market cap of $12.36 billion, a price-to-earnings ratio of 38.84, a PEG ratio of 0.57 and a beta of 0.28.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently modified their holdings of the business. Creative Planning increased its stake in BioMarin Pharmaceutical by 20.9% in the 3rd quarter. Creative Planning now owns 14,300 shares of the biotechnology company’s stock valued at $1,005,000 after buying an additional 2,475 shares during the period. Vontobel Holding Ltd. increased its stake in BioMarin Pharmaceutical by 73.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 6,050 shares of the biotechnology company’s stock valued at $425,000 after buying an additional 2,553 shares during the period. nVerses Capital LLC acquired a new position in BioMarin Pharmaceutical in the 3rd quarter valued at $28,000. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in BioMarin Pharmaceutical by 23.4% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 20,763 shares of the biotechnology company’s stock valued at $1,459,000 after buying an additional 3,939 shares during the period. Finally, Blue Trust Inc. increased its stake in BioMarin Pharmaceutical by 504.9% in the 3rd quarter. Blue Trust Inc. now owns 859 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 717 shares during the period. 98.71% of the stock is owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.